RESUMEN
OBJECTIVE: To evaluate the sedative, analgesic, and cardiorespiratory effects of intramascular (IM) romifidine in cats. STUDY DESIGN: Prospective, randomized experimental trial. ANIMALS: Ten healthy adult cats. METHODS: Romifidine (100, 200, and 400 microg kg(-1)) or xylazine (1 mg kg(-1)) was given IM in a cross-over study design. Heart rate (HR), respiratory rate (RR), rectal temperature (RT), hemoglobin saturation, oscillometric arterial pressure, and scores for sedation, muscle relaxation, position, auditory response, and analgesia were determined before and after drug administration. Time to recumbency, duration of recumbency, and time to recover from sedation were determined. Subjective evaluation and cardiorespiratory variables were recorded before and at regular intervals for 60 minutes after drug administration. RESULTS: Bradycardia developed in all cats that were given romifidine or xylazine. No other significant differences in physiologic parameters were observed from baseline values or between treatments. Increasing the dose of romifidine did not result in increased sedation or muscle relaxation. Cats given xylazine showed higher sedation and muscle relaxation scores over time. Analgesia scores were significantly higher after administration of romifidine (400 microg kg(-1)) and xylazine (1 mg kg(-1)) than after romifidine at 100 or 200 microg kg(-1). Duration of lateral recumbency was not significantly different between treatments; however, cats took longer to recover after administration of 400 micro g kg(-1) romifidine. CONCLUSIONS AND CLINICAL RELEVANCE: Bradycardia is the most important adverse effect after IM administration of romifidine at doses ranging from 100 to 400 microg kg(-1) or 1 mg kg(-1) of xylazine in cats. The sedative effects of romifidine at 200 microg kg(-1) are comparable to those of 1 mg kg(-1) of xylazine, although muscle relaxation and analgesia were significantly less with romifidine than with xylazine.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacocinética , Anestésicos/farmacocinética , Gatos/fisiología , Imidazoles/farmacología , Agonistas alfa-Adrenérgicos/administración & dosificación , Anestésicos/administración & dosificación , Animales , Temperatura Corporal/efectos de los fármacos , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/administración & dosificación , Inyecciones Intramusculares/veterinaria , Masculino , Relajación Muscular/efectos de los fármacos , Estudios Prospectivos , Respiración/efectos de los fármacosRESUMEN
OBJECTIVES: To evaluate the effects of a combination of tiletamine-zolazepam-romifidine-atropine in ocelots. DESIGN: Prospective experimental trial. ANIMALS: Eight captive adult ocelots (three females and five males). METHODS: Calculated doses of tiletamine-zolazepam (3.75 mg kg(-1)), romifidine (50 microg kg(-1)) and atropine (0.04 mg kg(-1)) were administered intramuscularly. After immobilization, animals were weighed and the real doses determined. Heart rate, respiratory frequency, noninvasive systolic, diastolic, and mean arterial pressure, arterial oxygen hemoglobin saturation, and rectal temperature were measured. Data were analyzed by means of anova for repeated measures, followed by the Tukey test to compare values over time. RESULTS: Doses administered were 3.4 +/- 0.6 mg kg(-1) of tiletamine-zolazepam, 0.04 +/- 7.0 mg kg(-1) of romifidine, and 0.03 +/- 0.007 mg kg(-1) of atropine. The mean time to recumbency and duration of immobilization were 7.0 +/- 4.5 and 109.2 +/- 27.9 minutes, respectively. The median times to standing and walking were 52.3 [0-90] and 2.3 [0-69.3] minutes, respectively. A decrease in heart rate was observed 45 minutes following drug administration. Arterial blood pressure was maintained during the study. CONCLUSIONS AND CLINICAL RELEVANCE: This protocol produced good immobilization in ocelots with minimal changes over time in cardiovascular parameters.
Asunto(s)
Anestésicos Disociativos/administración & dosificación , Carnívoros/fisiología , Animales , Atropina/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/administración & dosificación , Inyecciones Intramusculares/veterinaria , Masculino , Relajación Muscular/efectos de los fármacos , Oxígeno/sangre , Estudios Prospectivos , Respiración/efectos de los fármacos , Tiletamina/administración & dosificación , Zolazepam/administración & dosificaciónRESUMEN
The cardiovascular, respiratory, and anesthetic effects of medetomidine-ketamine (20 microg/kg bodyweight [BW] and 10 mg/kg BW) (MK group) or dexmedetomidine-ketamine (10 microg/kg BW and 10 mg/kg BW) (DK group) were studied in golden-headed lion tamarins. Heart rate decreased after administration of both combinations; this reduction was statistically greater in the DK group than in the MK group after 15 and 45 minutes. Systolic arterial pressure decreased in a similar way in both groups, except at 15 minutes, when systolic arterial pressure was significantly lower in the DK group. Diastolic arterial pressure, mean arterial pressure, respiratory rate, and rectal temperature were progressively reduced in all groups. Sedation time was significantly shorter and anesthesia time was significantly longer in the DK group compared with MK group. Anesthetic quality and analgesia scores were significantly greater at 5 and 15 minutes in the DK group compared with the MK group. The administration of dexmedetomidine-ketamine is as safe and effective as the administration of medetomidine-ketamine in tamarins.
Asunto(s)
Anestésicos Combinados , Anestésicos Disociativos , Callitrichinae/fisiología , Dexmedetomidina , Hipnóticos y Sedantes , Ketamina , Medetomidina , Analgesia/veterinaria , Anestésicos Combinados/farmacología , Anestésicos Disociativos/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Dexmedetomidina/farmacología , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Hipnóticos y Sedantes/farmacología , Ketamina/farmacología , Masculino , Medetomidina/farmacología , Distribución Aleatoria , Respiración/efectos de los fármacos , Seguridad , Factores de TiempoRESUMEN
OBJECTIVE: To determine sedative and cardiorespiratory effects of dexmedetomidine alone and in combination with butorphanol or ketamine in cats. DESIGN: Randomized crossover study. ANIMALS: 6 healthy adult cats. PROCEDURES: Cats were given dexmedetomidine alone (10 microg/kg [4.5 mg/lb], IM), a combination of dexmedetomidine (10 microg/kg, IM) and butorphanol (0.2 mg/kg [0.09 mg/lb], IM), or a combination of dexmedetomidine (10 microg/kg, IM) and ketamine (5 mg/kg [2.3 mg/lb], IM). Treatments were administered in random order, with > or = 1 week between treatments. Physiologic variables were assessed before and after drug administration. Time to lateral recumbency, duration of lateral recumbency, time to sternal recumbency, time to recovery from sedation, and subjective evaluation of sedation, muscle relaxation, and auditory response were assessed. RESULTS: Each treatment resulted in adequate sedation; time to lateral recumbency, duration of lateral recumbency, and time to recovery from sedation were similar among treatments. Time to sternal recumbency was significantly greater after administration of dexmedetomidine-ketamine. Heart rate decreased significantly after each treatment; however, the decrease was more pronounced after administration of dexmedetomidine-butorphanol, compared with that following the other treatments. Systolic and diastolic blood pressure measurements decreased significantly from baseline with all treatments; 50 minutes after drug administration, mean blood pressure differed significantly from baseline only when cats received dexmedetomidine and butorphanol. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that in cats, administration of dexmedetomidine combined with butorphanol or ketamine resulted in more adequate sedation, without clinically important cardiovascular effects, than was achieved with dexmedetomidine alone.
Asunto(s)
Butorfanol/farmacología , Sistema Cardiovascular/efectos de los fármacos , Gatos/fisiología , Dexmedetomidina/farmacología , Hipnóticos y Sedantes/farmacología , Ketamina/farmacología , Anestésicos Disociativos/farmacología , Animales , Estudios Cruzados , Combinación de Medicamentos , Frecuencia Cardíaca/efectos de los fármacos , Relajación Muscular/efectos de los fármacos , Respiración/efectos de los fármacosRESUMEN
OBJECTIVE: To determine sedative and cardiorespiratory effects of romifidine alone and romifidine in combination with butorphanol and effects of preemptive atropine administration in cats sedated with romifidine-butorphanol. DESIGN: Randomized crossover study. ANIMALS: 6 healthy adult cats. PROCEDURES: Cats were given saline (0.9% NaCl) solution followed by romifidine alone (100 microg/kg [45.4 microg/lb], i.m.), saline solution followed by a combination of romifidine (40 microg/kg [18.1 microg/lb], i.m.) and butorphanol (0.2 mg/kg [0.09 mg/lb], i.m.), or atropine (0.04 mg/kg [0.02 mg/lb], s.c.) followed by romifidine (40 microg/kg, i.m.) and butorphanol (0.2 mg/kg, i.m.). Treatments were administered in random order, with > or = 1 week between treatments. Physiologic variables were determined before and after drug administration. Time to recumbency, duration of recumbency, time to recover from sedation, and subjective evaluation of sedation, muscle relaxation, and analgesia were assessed. RESULTS: Bradycardia developed in all cats that received saline solution and romifidine-butorphanol or romifidine alone. Preemptive administration of atropine prevented bradycardia for 50 minutes in cats given romifidine-butorphanol. Oxyhemoglobin saturation was significantly decreased 10 minutes after romifidine-butorphanol administration in atropine-treated cats. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that administration of romifidine alone or romifidine-butorphanol causes a significant decrease in heart rate and that preemptive administration of atropine in cats sedated with romifidine-butorphanol effectively prevents bradycardia for 50 minutes.